Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;7(2):195-199.
doi: 10.1038/s41564-021-01046-z. Epub 2022 Jan 10.

Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults

Addi J Romero-Olmedo #  1 , Axel Ronald Schulz #  2 , Svenja Hochstätter  3 , Dennis Das Gupta  1 , Iiris Virta  2 , Heike Hirseland  2 , Daniel Staudenraus  1 , Bärbel Camara  1 , Carina Münch  3 , Véronique Hefter  3 , Siddhesh Sapre  3 , Verena Krähling  3 , Helena Müller-Kräuter  3 , Marek Widera  4 , Henrik E Mei #  2 , Christian Keller #  3 , Michael Lohoff #  5
Affiliations

Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults

Addi J Romero-Olmedo et al. Nat Microbiol. 2022 Feb.

Abstract

Here we compared SARS-CoV-2-specific antibody and T-cell responses between older adults (>80 years old, n = 51) and a younger control group (20-53 years old, n = 46) after receiving two doses of BNT162b2. We found that responses in older adults were generally lower, and we identified 10% low-/non-responders. After receiving a third vaccination with BNT162b2, 4 out of 5 low-/non-responders showed antibody and T-cell responses similar to those of responders after two vaccinations.

PubMed Disclaimer

References

    1. Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819–1829 (2021). - DOI
    1. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). - PubMed
    1. Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417–422 (2021). - DOI
    1. Brosh-Nissimov, T. et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. Clin. Microbiol. Infect. https://doi.org/10.1016/j.cmi.2021.06.036 (2021).
    1. Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270–274 (2020). - DOI

Publication types

MeSH terms

LinkOut - more resources